| 2026 Consensus Statement Update | 2022 Consensus Statement |
|---|---|
| Scenario 1 De novo metastatic patients or patients with a treatment-free interval of ≥ 12 months after the end of adjuvant trastuzumab or trastuzumab plus pertuzumab (IV or SC) based therapy: Taxane/trastuzumab/pertuzumab (IV or SC) is the preferred first line treatment. Trastuzumab deruxtecan (T-DXd) combined with pertuzumab is also an option. | Scenario 1 De novo metastatic patients or patients with a treatment-free interval of ≥ 12 months after the end of adjuvant therapy: Taxane/trastuzumab/pertuzumab is preferred first line treatment. |
References
CLEOPATRA, DB-09
Quality of evidence: I; Strength of recommendation: A